We are delighted to announce that Bioelectronic Medicine is now indexed in PubMed Central. This includes content published from 2018 onward.
As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
Announcing the launch of In Review
Aims and scope
Bioelectronic Medicine is an open-access journal that provides a necessary and specific publication platform for the growing field of Bioelectronic Medicine.
This field brings together material science, biochemistry, biophysics, molecular medicine, neuroscience, immunology, bioengineering, electrical engineering, mechanical engineering, computer science, mathematics, artificial intelligence, and other basic and clinical disciplines. Bioelectronic Medicine promises to bring new insights into the diagnosis and treatment of diseases and conditions as varied as cancer, rheumatoid arthritis, inflammatory bowel disease, obesity, diabetes, asthma, paralysis, blindness, bleeding, ischemia, organ transplantation, cardiovascular disease, neurodegenerative diseases, and others.
Bioelectronic Medicine focuses on electrical signaling in the nervous system. Insights into the regulatory functions of the nervous system and technologies that record, stimulate, or block neural signaling to affect specific molecular mechanisms are the primary focus of the journal. The journal will also feature bioelectronic approaches for monitoring and controlling biological processes, for providing insights into host and pathogen physiology and disease pathogenesis, and for restoring musculoskeletal function and mobility and treating paralysis, and many other conditions. In addition, developments in prostheses, robotics, and other relevant areas will be featured. Innovative preclinical research and development as well as clinical trials assessing new diagnostic and treatment advances will be well represented. Bioelectronic Medicine also welcomes related topics including ethics, community impact, regulatory and legal implications, reimbursement, and patient feedback in order to embrace multidisciplinary input across fields of science, technology, and healthcare.
Criteria to consider for studies involving lnc-RNAs or micro-RNAs:
· The proposed function of the lnc-RNA or miRNA should be validated by gain and loss of function studies.
· Primary cells should be used whenever possible to confirm findings in cell lines.
· In depth investigation in the signaling pathway(s) regulated by the RNA species should be conducted.
· Insight into the regulation of the RNA species and how it relates to the pathologic state should be provided.
· If applicable: Details of initial screen used to identify RNA species involvement in pathway/disease (number of subjects, statistical tests employed, percent change from controls.
Nobel congratulations to William G. Kaelin Jr
Molecular Medicine is happy to congratulate William G. Kaelin Jr on being a winner of The Nobel Prize in Physiology or Medicine 2019. Professor Kaelin Jr was chosen for his work on the discoveries of how cells sense and adapt to oxygen availability. He previously contributed an article to our journal, "The Molecular Basis of Von Hippel-Lindau Disease", which you can read here.
Bioelectronic Medicine now in PMC
Ultrasound-driven piezoelectric current activates spinal cord neurocircuits and restores locomotion in rats with spinal cord injury
Bioelectronic Medicine would like to recognize the efforts of the following peer reviewers, for their excellent service during the first and second quarter of 2020. These individuals have all exceeded expectations as far as acceptance rate, the number of completed reviews, and timeliness. The journal cannot succeed without its peer reviewers, and we thank these hard-working members of our network:
Second Quarter of 2020: Dr. Hojjat Salmasian
First Quarter of 2020: Eric H. Chang, Ph.D.
Featured series: "Bioelectronic medicine: engineering advances, physiological insights, and translational applications"
Our new thematic series, guest edited by Stavros Zanos, Timir Datta-Chaudhuri, Vasiliki Giagka, Loren Rieth, and Theodoros Zanos, is now open for submissions. Our field has grown significantly in the last decade. It is an intrinsically multidisciplinary field and therefore advances require collaboration across diverse areas of expertise. For this series we would like to invite original contributions and reviews in the following areas: novel neural interfaces; methods, systems, and applications of targeted neuromodulation; advances in bioelectronic data analytics; new implantable bioelectronic devices; and translation of bioelectronic therapies. Please see here for more details.
Featured cross-journal series: Molecular mechanisms and therapeutic relevance of neuro-immune communication
Our new cross-journal thematic series (published in conjunction with Molecular Medicine), calls for submissions focusing on the molecular mechanisms and therapeutic exploration at the interface between the immune and nervous systems in health and disease and the therapeutic exploration of this insight. It will also cover emerging areas such as the neuronal regulation of hematopoiesis and innate and adaptive immunity. The series is guest edited by Sangeeta Chavan, Colin Reardon, and Niccolò Terrando. Find more information here.
Our journal is proud to announce that its fourth summit will be held in Fall 2020. The focus will be "Technology Targeting Molecular Mechanisms". The meeting will call international attention to bioelectronic medicine as the platform for new developments in healthcare, technology, and science. Leaders in the field will discuss current progress, challenges, and future developments. Find out more
Announcing our new article types
Our journal is proud to offer four new article types, ready for submissions!
- Mini-reviews, which provide a concise summary of a specific research topic or field relevant to our scope.
- Perspectives, which grants the opportunity to write about the current state and recent developments of a research field or topic within our scope and point to associated challenges and future directions.
- Opinions, written with a specific focus on a previously published article which has had a major impact on the field.
- Commentaries, invited pieces which provide further discussion on a primary research manuscript.
Please see our Submission Guidelines page for more.
About the Editors
Dr Kevin J Tracey (Editor-in-Chief) is president of The Feinstein Institutes for Medical Research, and professor of Molecular Medicine and Neurosurgery at the Zucker School of Medicine. He is a leader in the study of the molecular basis of inflammation. He and his colleagues identified the neural mechanism for controlling the immunological responses to infection and injury, and developed devices to replace anti-inflammatory drugs in clinical trials of rheumatoid arthritis, a new field termed bioelectronic medicine. The recipient of numerous awards and honors, including an honorary degree from the Karolinska Institutet, Dr Tracey is a fellow in the American Association for the Advancement of Science, and a member in the American Society for Clinical Investigation, and the Association of American Physicians. He is co-founder and Councilor of the Global Sepsis Alliance.
Dr Tracey graduated summa cum laude from Boston College, majoring in chemistry, and received his MD from Boston University. He trained in neurosurgery at the New York Hospital/Cornell University Medical Center, and was guest investigator at The Rockefeller University. Since 1992, he has directed the Laboratory of Biomedical Science in Manhasset, NY, where in 2005 he was appointed president of the Feinstein Institutes. Dr Tracey delivers lectures nationally and internationally on inflammation, sepsis, the neuroscience of immunity, and bioelectronic medicine. He is the author of Fatal Sequence (Dana Press) and more than 370 scientific papers.
Valentin Pavlov, The Feinstein Institutes for Medical Research, USA- Executive Editor
Sonya VanPatten, The Feinstein Institutes for Medical Research, USA- Coordinating Editor
The Editors of Bioelectronic Medicine welcome authors to send any pre-submission inquiries they might have here. We ask that you please include “Pre-submission inquiry” in the subject line of your email and that you include the title and abstract of your proposed submission within the message. Our Editors will do their best to respond to you in a timely manner.
If you enjoy Bioelectronic Medicine, we invite you to visit Feinstein’s flagship journal, Molecular Medicine (published by BMC). Published for nearly a quarter of a century and fully indexed, Molecular Medicine focuses on recent insights into the molecular mechanisms of disease pathogenesis, which may lead to the design of specific tools for disease diagnosis, treatment, or prevention. You will find material relevant to the genetic, molecular, or cellular basis of key physiologic or disease processes, as well as content which describes the clinical implications of these findings, at a level approachable by our broad audience.
About Feinstein Institutes for Medical Research
Bioelectronic Medicine is published in partnership with The Feinstein Institutes for Medical Research. As the research arm of Northwell Health, the largest healthcare provider in New York, it is home to 50 research laboratories and to clinical research throughout dozens of hospitals and outpatient facilities. The Feinstein Institutes include 4,000 researchers and staff who are making breakthroughs in molecular medicine, genetics, oncology, brain research, mental health, autoimmunity, and bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how the Feinstein Institutes empower imagination and pioneers discovery, visit FeinsteinInstitute.org.
Annual Journal Metrics
30 days to first decision for reviewed manuscripts only
28 days to first decision for all manuscripts
56 days from submission to acceptance
28 days from acceptance to publication